2024年體外診斷試劑業務展望(更新6次)
市場調查報告書
商品編碼
1458173

2024年體外診斷試劑業務展望(更新6次)

In Vitro Diagnostics Business Outlook, 2024 (6 Updates)

出版日期: | 出版商: Kalorama Information | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

體外診斷業務展望每雙月出版一次,每年六次。

樣本

該報告探討了體外診斷業務的前景,並提供了獨特的資訊和數據,包括:

目錄

  • 市場數據和預測(成長率、市場規模、市場佔有率)以確定成長機會
  • 全面瞭解 IVD 市場,涵蓋測試類別和公司概況
  • 併購活動、精心挑選的合作夥伴關係和合作、合作協議等。
  • 對策略規劃有用的產業和區域趨勢
  • 分析新聞和事件,報導難以找到的新聞
簡介目錄
Product Code: 24-014

"In Vitro Diagnostics Business Outlook" is a bimonthly publication with six issues annually.

SAMPLE VIEW

"In Vitro Diagnostics Business Outlook" offers information and data that you cannot get anywhere else, including:

  • Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
  • A comprehensive view of the IVD market with test categories covered and company briefs
  • M&A activities, selected partnerships & collaborations, partnership deals, and more
  • Industry & region watch to help tailor strategies
  • Analysis of news and events and reporting on news not easily available

Table of Contents

Volume 3, Issue 1 – Focus on Molecular HLA Testing

Market Analysis: Molecular HLA/Transplant Testing

  • Overview of Molecular HLA/Transplant Testing
  • Market Outlook
  • Regional Market
  • Top Company Briefs
    • Immucor
    • Luminex/DiaSorin
    • CareDx
    • Thermo Fisher Scientific
  • Executive News Briefing
    • DEKFI Diagnostics Appoint New CEO
    • Onera Raises $32 Million in Funding
    • Cleveland Diagnostics Completes $75 Million in Funding
  • Financial Highlights: Agilent and Hologic
  • Agilent Full Year Fiscal 2023 Sales up 1.5% in Core Business YOY
    • Figure: Agilent Sales, by Business (Agilent CrossLab Group, Diagnostics and Genomics Group, Life Sciences and Applied Markets Group), FY 2022 and FY 2023
    • Figure: Agilent Sales, by Business (Agilent CrossLab Group, Diagnostics and Genomics Group, Life Sciences and Applied Markets Group), FY 2023 Quarterly Performance
    • Table: Agilent Revenue Mix, by Type (Consumables/Services/Informatics and Instruments), FY 2023 (%)
    • Figure: Agilent FY 2023 Regional Sales Breakdown Distribution, by Region (Americas, Asia Pacific, Europe) (%)
  • Hologic Supports Strong Financial Performance in Full-Year Fiscal Year Guidance
    • Table: Hologic Diagnostic Sales Performance, by Product Group (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), FY 2023 ($ millions)
    • Figure: Hologic Revenue, by Product Group (Blood Screening, Cytology & Perinatal, Molecular Diagnostics), FY 2022 and FY 2023 ($ millions)
    • Figure: Hologic Geographic Revenue Distribution, by Region (Asia Pacific, Europe, United States, All Others), FY 2023 (%)
  • Diagnostic Market Mergers, Acquisitions and Partnership Deals
  • Mergers and Acquisitions
    • Table: Selected Diagnostic Market Mergers and Acquisitions Deals Partnerships and Collaborations
  • Industry Watch
  • COVID-19 Update
  • Region Watch
    • India
      • Figure: India Real GDP Growth, Inflation Rate (consumer prices), 2017-2024
      • Figure: India IVD Market Distribution of Sales, by Broad IVD Segment (Chemistry/Hematology/Coagulation, Histology/Cytology, Immunoassays, Microbiology/Virology, Point-of-Care Glucose, Other Segments), 2023 (%)
    • Saudi Arabia
      • Figure: Saudi Arabia Population Pyramid, 2023 and 2053
      • Figure: Saudi Arabia Total Annual Liquid Fuels Production and Consumption, 2013-2022 (millions of barrels)
      • Figure: Saudi Arabia IVD Market Share, by Broad IVD Segment (Chemistry/Hematology/Coagulation, Histology/Cytology, Immunoassays, Microbiology/Virology, Point-of-Care Glucose, Other Segments), 2023
    • Broad-based Company Announcements
    • QuidelOrtho Obtains FDA Nod
    • Illumina Plans to Divest Grail
    • Roche to Acquire LumiraDx
    • QIAGEN Expands Footprint with New Regional Headquarters in Middle East

Volume 3, Issue 2 – Focus on Immunoassay Overview

  • Market Analysis
  • Overview of IVD Immunoassay
  • Market Outlook
    • Table: Global Lab-Based Immunoassay Market by Segment, 2023-2028 ($ millions)
    • Figure: Global Lab-Based Immunoassay Market, by Segment, 2023-2028 ($ millions)
  • Regional Market
    • Table: Global Immunoassay Market (Lab-Based) Sales Distribution, by Region, 2023 (%) (North America, Europe, Asia Pacific, Latin America, Middle East, Africa)
    • Figure: Global Immunoassay Market Sales Distribution, Top 10 Country Markets, 2023 (%)
  • Top Company Briefs
    • Roche
    • Abbott Diagnostics
    • Siemens Healthineers
    • Other Selected Immunoassay News
  • Executive News Briefing
    • NOWDiagnostics Selects New Science Officer
    • Freenome Raises $254 Million in New Funding
    • QuidelOrtho Axes CEO
    • Agilent CEO to Retire
  • Financial Highlights: Bio-Rad Laboratories and Veracyte
  • Bio-Rad Laboratories Reports Full-Year 2023 Clinical Diagnostics Revenues up 3.2% over previous year
    • Table: Bio-Rad Laboratories Net Sales, 2021-2023 ($M)
    • Figure: Bio-Rad Laboratories Sales by Business, 2022 vs. 2023, $M
    • Figure: Bio-Rad Laboratories Quarterly Performance by Business, 2022 vs. 2023 ($M)
    • Figure: Bio-Rad Laboratories 2022 and 2023 Regional Sales Breakdown Distribution
  • Veracyte Reported Strong Performance in 2023
    • Figure: Veracyte 12-Month (FY22 and FY23) Sales by Division (Testing, Product, Biopharmaceutical and Other), Thousands USD
  • Diagnostic Market Mergers, Acquisitions and Partnership Deals
  • Mergers and Acquisitions
    • Table: Selected Diagnostic Market Mergers and Acquisitions Deals
  • Partnerships and Collaborations
  • Industry Watch
  • Virus Testing Update
  • Region Watch
    • Peru
      • Figure: Peru Population Distribution by Broad Age Group, 2023 and 2040 Estimates
      • Figure: Peru GDP Value and Growth by Year, 2010-2022
      • Figure: Peru COVID-19 Lab Samples Tested and Positivity by Region, Cumulative 2020-2023
    • South Africa
      • Figure: South Africa Population Pyramid, 2023 and 2033 Estimates
      • Figure: South Africa GDP, Composition by Sector (Agriculture, Industry, Services)
    • Broad-based Company Announcements
    • Werfen Receives CE Mark for Aptiva Antiphospholipid Syndrome
    • DiaSorin Nabs FDA Clearance for New LIAISON PLEX System
    • T2 Biosystems Offers Expanded Panel
    • Cepheid Received FDA Clearance for Xpert Xpress GBS
    • DiaCarta Collaboration to Launch Prostate Cancer LDT

Volume 3, Issue 3 – Clinical Chemistry

  • Market Analysis: Clinical Chemistry
  • Overview of Clinical Chemistry Market
  • Market Outlook
    • Table: Clinical Chemistry Diagnostic Sales, by Broad Test Category, 2023 ($ millions)
    • Figure: Clinical Chemistry Diagnostic Market Distribution, by Broad Test Category, 2023 (%)
  • Major Product Activity
    • Lab-based Clinical Chemistry
    • Table: Market Summary: Lab-based Clinical Chemistry Market, by Segment, 2023 and 2028 ($ millions)
    • Point-of-Care Clinical Chemistry
    • Table: Market Summary: POC-based Clinical Chemistry Market, 2023 and 2028 ($ millions)
  • Regional Market
    • Figure: Global Clinical Chemistry Sales Estimates and Projection, by Region, 2023 and 2028 ($ millions)
    • Table: Global Clinical Chemistry Sales Distribution, by Region, 2023 (%)
  • Top Company Briefs
    • Roche
    • Abbott
    • Danaher
  • Executive News Briefing
    • Cue Health Calls It Quits
    • Allenz Health Secures $60 Million in Funding
    • Next Gen Diagnostics Welcomes New Scientific Advisory Board Member
    • Next Gen Diagnostics Opens First U.S. Laboratory
  • Financial Highlights: bioMérieux & Sekisui Diagnostics
    • Figure: bioMérieux Sales Distribution, by Business Segment, 2023 (%)
    • Table: bioMérieux Financial Review, by Business Segment, FY 2022 – FY 2-23 (€M)
    • Figure: bioMérieux FY 2022 vs FY 2023 Regional Sales Breakdown (€M)
    • Table: Sekisui Chemical Financial Results, FY 2022 and FY 2023 (Billions of Yen)
    • Table: Sekisui Chemical Annual Overview and Focus, FY 2023 and FY 2024 (Billions of Yen)
    • Table: Sekisui Chemical Net Sales, by Segment, FY22 and FY23 (Billions of Yen)
    • Figure: Sekisui Chemical Medical Division, Revenue Mix, by Type, by Quarter, Q1 FY22 – Q4FY23 (Millions of Yen)
  • Diagnostic Market Mergers, Acquisitions and Partnership Deals
  • Mergers and Acquisitions
    • Table: Selected Diagnostic Market Mergers and Acquisitions Deals
  • Partnerships and Collaborations
  • Industry Watch
  • COVID-19/Flu Update
  • Region Watch
    • Japan
      • Figure: Japan National Health Expenditures, Year-on-Year Growth Rate, 1985-2019 (Yen trillion, %)
      • Figure: Japan: Changes in Number of Hospitals, by Hospital Type, 2015-2019
      • Figure: Japan: Changes in Number of Beds, by Bed Type and Number of Beds per Hospital, 2015-2019
      • Figure: Japan: Changes in Average Length of Stay, by Bed Type, 2015-2019
      • Figure: Japan IVD Market, by Segment, 2023 (%)
  • Broad-based Company Announcements
  • Announcements
  • QIAGEN Launches Gastrointestinal Molecular Panel in the United States
  • Illumina Spins Off Grail
  • QIAGEN Discontinues NeuMoDx System
  • DiaSorin Nabs Clearance for LIAISON PLEX Blood Culture Yeast Assay
  • Genetic Signatures Granted FDA Clearance for GI Kit

Volume 3, Issue 4 – Blood Screening

  • OVERVIEW OF BLOOD SCREENING
  • MARKET OUTLOOK
    • Figure: Blood Screening Market, 2019-2029 ($ billion)
    • Figure: Blood Screening Sales, by Test Method, 2024 and 2029 ($ billion) (Immunoassay Screen, NAT Screens)
    • Figure: Blood Donation Screening Market Distribution, by Analyte, 2024 (%) (Hepatitis, HIV, Other)
  • REGIONAL MARKET
    • Table: Estimated Blood Donations, by WHO Region, 2018
    • Figure: Whole Blood Donations per 1000 Population, 2018
    • Table: Blood Screening Market Distribution, by Global Region, 2024 (%) (Asia Pacific, Europe, North America, RoW)
    • Figure: Blood Screening Market Distribution of Sales, by Global Region (%) (Asia Pacific, Europe, North America, RoW)
  • Segment Activity by Region
    • Immunoassays
    • Figure: Market Summary: Immunoassay Blood Screening Market, Distribution of Sales, by Region, 2024 (%) (Asia Pacific, Europe, North America, RoW)
    • Molecular
    • Figure: Market Summary: NAT Blood Screening Market, Distribution of Sales by Region (North America, Europe, Asia Pacific, RoW), 2024
  • TOP COMPANY BRIEFS
  • Roche
  • Grifols
  • Abbott
  • EXECUTIVE NEWS BRIEFING
  • BRIEFS
  • Trinity Biotech Engages New CCO
  • BillionToOne Closes Financing Deal
  • OraSure Technologies Elects New Board Member
  • Viome Life Sciences Secures $25 Million in Financing
  • Syantra Raises $3.6 Million in A-1 Round Financing
  • FINANCIAL HIGHLIGHTS: DEXCOM AND EXACT SCIENCES
  • Dexcom Revenues Increase 15% (+$133 million) in Q2 2024
    • Figure: Dexcom Revenue Mix, by Product Segment, Q2 2023 and Q2 2024
    • Figure: Dexcom Revenue Mix by Product Segment, By Quarter 2022 – Q2 2024
    • Table: Dexcom Geographic Revenues, by Region, Q2 2023 and Q2 2024 ($ million)
  • Exact Sciences Reports it : Tested a Record Number of Cancer Patients with Oncotype DX
    • Figure: Exact Sciences Revenue Mix, by Product Segment, Q2 2023 vs Q2 2024 ($ million)
    • Figure: Exact Sciences Revenue Mix, by Product Segment, by Quarter 2022-Q2 2024 ($ million)
  • DIAGNOSTIC MARKET MERGERS, ACQUISITIONS AND PARTNERSHIP DEALS
  • PARTNERSHIPS AND COLLABORATIONS
  • MERGERS AND ACQUISITIONS
    • Table: Selected Diagnostic Market Mergers and Acquisitions Deals
  • REGION WATCH
    • Figure: South Korea GDP, GDP (PPP), and Health Spending, CAGR 2005-2010, 2010-2015, 2015-2020 and 2020-2023 (%)
    • Figure: South Korea Medical Tourism Visits Reported, 2009-2023 (# of patients)
    • Figure: South Korea Old-Age Dependency Ratio and Aging Index, 1980-2065
  • BROAD-BASED COMPANY ANNOUNCEMENTS
  • ANNOUNCEMENTS
  • Foundation Medicine Gets the Nod for Its Companion Diagnostics
  • QuidelOrtho Proud to Announce Clearance for VITROS Syphilis Assay
  • AliveDx Receives IVDR-CE Mark for Multiplexed Assay
  • T2 Biosystems Scores FDA Pediatric Clearance
  • ID-FISH Technology Announces FDA Nod for its Lyme ImmunoBlot

Volume 3, Issue 5 – Point-of-Care (POC)

  • Market Analysis: IVD POC Testing
  • Overview of IVD POC Testing
  • Market Outlook
    • Table: Global POC Diagnostic Market, by Broad Segment, 2024 and 2029 ($ million) (professional testing, self-testing)
    • Figure: Point-of-Care Diagnostics (COVID-19 vs. non-COVID testing), 2020-2024 ($ million)
    • Figure: Global POC Diagnostic Market Distribution, by Segment, 2024 (%) (Cardiac Care; Coagulation; Critical Care; Drug of Abuse; Fecal Occult Blood; Glucose; Hematology; Infectious Disease Lipid [Cholesterol]; Pregnancy/Fertility; Urinalysis; Others)
  • Selected Product Activity
  • Regional Market
    • Figure: POC Diagnostics Market Value, by Global Region, 2024 ($ million) (North America, Europe, Asia Pacific, Latin America, Middle East, Africa)
  • Company Briefs
  • Abbott Diagnostics
  • Dexcom
  • Roche
  • Executive News Briefing
  • Briefs
  • Quanterix Appoints New Member to Board of Directors
  • Beckman Coulter Appoints New President
  • MARAbio Raises $19 Million in Series A Funding
  • Amprion Makes Advances in Series B Financing
  • Sunbird Bio Closes $14 Million Financing Round
  • Bruker Reported 17% Growth in Second Quarter 2024 and 11% Growth for the First Six Months
    • Figure: Bruker Corporation Sales, by Business, H1 2023 Compared to H1 2024 (Bruker BioSpin, Bruker CALID, Bruker Nano, BEST, Eliminations)
    • Figure: Bruker CALID Quarterly Performance, Sales by Quarter, Q1 2022 – Q2 2024
    • Figure: Bruker Corporation H1 2023 and H1 2024 Regional Sales Breakdown Distribution (Asia Pacific, Japan; Europe; United States; Other)
  • Myriad Genetics Reports 13% Revenue Growth in First Half 2024
    • Table: Myriad Genetics Revenue Mix, by Product, H1 2023 vs H1 2024 ($ million) (Hereditary Cancer; Pharmacogenomics; Prenatal; Tumor Profiling)
    • Figure: Myriad Genetics Revenue Mix, by Business Unit, Quarterly Performance Q1 2023 through Q2 2024 ($ million) (Mental Health, Oncology, Womens Health)
  • Diagnostic Market Mergers, Acquisitions and Partnership Deals
  • Partnerships and Collaborations
  • Mergers and Acquisitions
    • Table: Recent Diagnostic Market Mergers, Acquisitions and Partnership Deals
  • Industry Watch
  • Industry Watch COVID-19/Flu Update
  • Region Watch
  • Finland
    • Figure: Finland GDP Value and Growth, by Year, 2013-2023 ($ billion)
    • Figure: Finland Social Protection Expenditure by Function, 1995-2022 in 2022 Prices (€ billion)
    • Figure: Finland IVD Market, 2019-2024 ($ million)
  • Broad-based Company Announcements
  • Announcements
  • Roche Launches TAGS Technology Test
  • Exact Sciences Welcomes New Cologuard Plus Test
  • PreAnalytiX Launches PAXgene Urine Liquid Biopsy Set
  • Abionic Launches Early Sepsis Test
  • QIAGEN Expands Liquid Biopsy Portfolio
  • FoundationOne Gains Liquid CDx Approval
  • Revvitys Euroimmun Announces Groundbreaking Launch in the EU

Volume 3, Issue 6 – Glucose Testing

MARKET ANALYSIS: IVD GLUCOSE TESTING

OVERVIEW OF IVD GLUCOSE TESTING

  • MARKET OUTLOOK
    • Table: Global Diabetes Sales, by Test Category, 2024-2029 ($ million) (Glucose OTC; Glucose Professional; Glucose, Continuous; HbA1c POC; HbA1c Lab)
    • Figure: Global Diabetes Testing Market, by Segment with CAGR 2024-2029 ($ million) (Glucose OTC; Glucose Professional; Glucose, Continuous; HbA1c POC; HbA1c Lab)
  • REGIONAL MARKET
    • Figure: Global Diabetes Prevalence, 20-79y, 2021 Estimates (per 1,000s)
    • Figure: Global Distribution, Diabetes Test Market, 2024 (%) (Glucose, HbA1c)
  • COMPANY BRIEFS
  • Abbott Diagnostics
  • Dexcom
  • Roche

EXECUTIVE NEWS BRIEFING

  • BRIEFS
  • Agilent Reorganizes Business Units
  • Natera Co-Founder Named R&D Leader of the Year
  • QIAGEN Moves QIAstat-Dx to Drive Growth
  • OraSure Receives Funding
  • AmplifiDx Captures Additional Funding
  • 52North Closes $6 Million in Funding

FINANCIAL HIGHLIGHTS: ABBOTT LABORATORIES, QIAGEN

  • ABBOTT CONTINUES STEADY PERFORMANCE IN 2024; 9M SALES INCREASE 3.7%
    • Figure: Abbott Sales by Business, 9M 2023 and 9M 2024 ($ million)
    • Table: Diagnostic Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
    • Figure: Diagnostic Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
    • Table: COVID-19 Test Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
    • Figure: Diabetes Care, Abbott Laboratories, 9M 2023 and 9M 2024 ($ million)
  • QIAGEN REPORTS STRONG PERFORMANCE IN Q3 2024; RAISES GUIDANCE
    • Figure: QIAGEN Revenue Mix by Business Segment, 9M 2024 ($ million) (Molecular Diagnostics, Life Sciences)
    • Figure: QIAGEN Sales by Product Group, 9M 2024 ($ million) (Sample Technologies, Diagnostic Solutions, PCR/Nucleic Acid Amplification, Genomics/NGS, Other)
    • Table: QIAGEN Sales, by Product Type, 9M 2023 and 9M 2024 ($ million) (CAGR %) (Consumables and Related Revenues, Instruments)
    • Figure: QIAGEN Diagnostic Solutions Sales, by Segment, 9M 2023 and 9M 2024 ($ million) (QuantiFERON, QIAstat-Dx, NeuMoDx, Other)
    • Figure: QIAGEN Sales, by Geographic Region, 9M 2023 and 9M 2024 ($ million) (Americas, EMEA, Asia Pacific/Japan)

DIAGNOSTIC MARKET MERGERS, ACQUISITIONS AND PARTNERSHIP DEALS

  • PARTNERSHIPS AND COLLABORATIONS
  • MERGERS AND ACQUISITIONS
    • Table: Recent Diagnostic Market Mergers, Acquisitions and Partnership Deals, Dec. 2023-Nov. 2024

INDUSTRY WATCH

  • INDUSTRY WATCH COVID-19/FLU UPDATE

REGION WATCH

  • VIETNAM
    • Figure: Vietnam GDP, Composition by Sector, 2023 (%) (Agriculture, Forestry, Fishery; Industry, Construction; Services)
    • Figure: Vietnam GDP Value and Growth by Year, 2015-2023 ($ billion)

BROAD-BASED COMPANY ANNOUNCEMENTS

  • ANNOUNCEMENTS
  • Roche Receives FDA Expanded Approval
  • Foundation Medicine Received FDA Companion Diagnostic Approval
  • Deepull Receives FDA Breakthrough Device Designation
  • bioMérieux Snags Clearance for Tropical Fever Panel
  • Roche Receives CE Mark for New Cobas Systems 2.0
  • Agilent Received Certification for Companion Diagnostic